Leptomeningeal Disease
16
7
10
1
Key Insights
Highlights
Success Rate
25% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
18.8%
3 terminated out of 16 trials
25.0%
-61.5% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (16)
Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD
ctDNA-Guided Intraventricular Therapy for CNS Malignancies
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
Non Interventional German Leptomeningeal Disease Register
Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
B7-H3.CD28Z.CART in CNS Neoplasms
Study Assessing QBS72S For Treating Brain Metastases
Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)
Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC